Oppenheimer Global Opportunities Fund invests in companies that are developing breakthrough drugs that can potentially treat cancer more effectively without debilitating side effects, make it easier for patients to manage pain, and possibly even lower the cost of treatment.

2017-08-10 00:00:00

While inflation stubbornly refuses to rise, OppenheimerFunds CIO Krishna Memani says the Fed is struggling with it's message.

2017-06-16 00:00:00

OppenheimerFunds' CIO Krishna Memani offers his outlook for the second half of 2017, including thoughts on monetary policy, international equities and emerging market credit.

George Evans, CIO Equities and Portfolio Manager at OppenheimerFunds, sees past the short-term noise in investing. He explains how the International Growth Fund has an eye for the future.

2017-08-24 12:03:47

This secular bull market—the least loved in memory—is now more than 100 months old, and up by 265% from its bottom on March 9, 2009. Are we near the end?

The excess returns of revenue-weighted strategies over market-capitalization strategies are apparent across the large-, mid- and small-cap company universe and may serve as an appropriate core equity replacement in investors' portfolios.